Samsung Bioepis Successfully Resolves Patent Disputes with Johnson & Johnson
- Samsung Bioepis has successfully resolved all patent litigation with Johnson & Johnson through a settlement & license agreement. This significant development clears the legal obstacles for the US commercialization of SB17 (biosimilar ustekinumab)
- The license period is set to commence on Feb 22, 2025, with specific terms remaining confidential. SB17 serves as an alternative for plaque psoriasis, CD, UC, & active PsA – indications for which Stelara is approved
- The BLA for SB17 is currently under review by the US FDA. Upon approval, SB17 will be commercialized in the US by Sandoz, as outlined in the development & commercialization agreement between Samsung Bioepis & Sandoz, signed in Sep 2023. This collaboration extends to the markets of the US, Canada, EEA, Switzerland, and UK
Ref: Samsung Bioepis | Image: Samsung Bioepis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at firstname.lastname@example.org.